QuantumPharm, Inc. (HK:2228) has released an update.
QuantumPharm Inc. has released its interim financial results for the first half of 2024, revealing a significant loss of RMB 1,237,550,000, almost double from the previous year’s RMB 620,297,000. Despite an increase in revenue to RMB 102,630,000 from RMB 79,967,000, the company’s research and development expenses and other costs contributed to the overall loss. The report indicates a challenging period for QuantumPharm, with the company urging caution regarding forward-looking statements.
For further insights into HK:2228 stock, check out TipRanks’ Stock Analysis page.